{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ustekinumab+90+mg",
    "query": {
      "intervention": "Ustekinumab 90 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 42,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ustekinumab+90+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T08:10:34.765Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01090063",
      "title": "Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Moderate to Severe Palmar Plantar Psoriasis"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 26,
      "start_date": "2010-02",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2016-10-28",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01090063"
    },
    {
      "nct_id": "NCT00267969",
      "title": "A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor Research & Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 766,
      "start_date": "2005-12",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2013-06-17",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00267969"
    },
    {
      "nct_id": "NCT02968108",
      "title": "A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 45,
      "start_date": "2017-01-18",
      "completion_date": "2022-03-18",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02968108"
    },
    {
      "nct_id": "NCT03782376",
      "title": "A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Ustekinumab approximately 6 mg/kg (IV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (SC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (IV)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 90 mg (SC) Group 1",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 90 mg (SC) Group 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen-Cilag Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2018-12-20",
      "completion_date": "2023-01-10",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 28,
      "location_summary": "La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03782376"
    },
    {
      "nct_id": "NCT01713400",
      "title": "Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft vs. Host Disease"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus (TAC)",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 54,
      "start_date": "2013-02-25",
      "completion_date": "2018-06-14",
      "has_results": true,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01713400"
    },
    {
      "nct_id": "NCT04978493",
      "title": "A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "BI 706321",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 49,
      "start_date": "2021-12-02",
      "completion_date": "2024-08-08",
      "has_results": true,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 15,
      "location_summary": "Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Inverness",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04978493"
    },
    {
      "nct_id": "NCT02203032",
      "title": "A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for guselkumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 872,
      "start_date": "2014-10-07",
      "completion_date": "2016-05-24",
      "has_results": true,
      "last_update_posted_date": "2017-09-12",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02203032"
    },
    {
      "nct_id": "NCT01009086",
      "title": "A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Psoriatic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 45 mg",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 90 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 615,
      "start_date": "2009-12",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2015-03-03",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 26,
      "location_summary": "Encinitas, California • La Jolla, California • San Diego, California + 23 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009086"
    },
    {
      "nct_id": "NCT00771667",
      "title": "A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo (IP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 1mg/kg (IP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 3 mg/kg (IP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 6 mg/kg (IP)",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV - Responder - Placebo SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Responder - Placebo SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Nonresponder - Placebo SC (MP)",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 526,
      "start_date": "2008-12",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-04-01",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 88,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00771667"
    },
    {
      "nct_id": "NCT02349061",
      "title": "A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Ustekinumab IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo Infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo SC",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab SC",
          "type": "DRUG"
        },
        {
          "name": "Concomitant Medication",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 102,
      "start_date": "2015-10-15",
      "completion_date": "2019-03-13",
      "has_results": true,
      "last_update_posted_date": "2020-03-24",
      "last_synced_at": "2026-09-29T08:10:34.765Z",
      "location_count": 12,
      "location_summary": "Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349061"
    }
  ]
}